Adline Chem Lab
KAMRONLABORATORIESLTD NSE
Adline Chem Lab
HealthcareNSE: KAMRONLABORATORIESLTD BSE: 524604 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹6.70 Cr
Volatility
Low Risk
P/E Ratio
-36
EBITDA
₹-0.20 Cr
Return on Equity
15.84%
Debt to Equity
0
Book Value
₹-3.03
52W High
₹17.06
52W Low
₹7.6
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
2- Company has low interest coverage ratio.
- Promoter holding is low: 25.8%
Growth Rate
Revenue Growth
-100%
Net Income Growth
200% higher than
3Y
Cash Flow Change
30.43% higher than
3Y
ROE
78.98% higher than
3Y
ROCE
426%
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.08 | 0.03 | 0 | 0.07 | 0.1 | 0.07 | 0.1 | 0.06 | 0.03 | 0.05 | 0.03 | 0.08 | 0.04 |
| Operating Profit | -0.08 | -0.03 | 0 | -0.07 | -0.1 | -0.07 | -0.1 | -0.06 | -0.03 | -0.05 | -0.03 | -0.08 | -0.04 |
| Other Income | 0 | 0 | 0 | 0.03 | 0 | 0 | 0 | 0.25 | 0 | 0 | 0 | 0.01 | 0.12 |
| Interest | 0 | 0.03 | 0.03 | 0 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.08 | -0.06 | -0.03 | -0.04 | -0.13 | -0.1 | -0.13 | 0.16 | -0.06 | -0.08 | -0.07 | -0.11 | 0.03 |
| Tax % | 0% | -16.67% | -33.33% | 0% | -7.69% | -10% | -7.69% | -31.25% | -16.67% | -12.5% | -14.29% | -9.09% | -33.33% |
| Net Profit | -0.08 | -0.05 | -0.02 | -0.04 | -0.13 | -0.09 | -0.12 | 0.21 | -0.05 | -0.07 | -0.06 | -0.09 | 0.04 |
| EPS in Rs | -0.14 | -0.09 | -0.03 | -0.07 | -0.22 | -0.15 | -0.21 | 0.36 | -0.09 | -0.12 | -0.1 | -0.15 | 0.07 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.36 | 16.94 | 17.18 | 8.1 | 5.59 | 6.59 | 6.33 | 0.74 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 14.42 | 16.5 | 15.97 | 7.23 | 5.01 | 9.91 | 6.56 | 1.04 | 0.8 | 0.18 | 0.3 | 0.2 | 0.2 |
| Operating Profit | 0.94 | 0.44 | 1.21 | 0.87 | 0.58 | -3.32 | -0.23 | -0.3 | -0.8 | -0.18 | -0.3 | -0.2 | -0.2 |
| OPM % | 6.12% | 2.6% | 7.04% | 10.74% | 10.38% | -50.38% | -3.63% | -40.54% | — | — | — | — | — |
| Other Income | 0.08 | 0.1 | 0.08 | 0.21 | 0.25 | 0.26 | 0 | 1.33 | -3.35 | 0 | 0.25 | 0.01 | 0.13 |
| Interest | 0.48 | 0.44 | 0.32 | 0.34 | 0.07 | 0.02 | 0.03 | 0.01 | 0 | 0.12 | 0.16 | 0.13 | 0.16 |
| Depreciation | 0.51 | 0.09 | 0.96 | 0.73 | 0.73 | 0.42 | 1.02 | 0.35 | 0.09 | 0 | 0 | 0 | 0 |
| PBT | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | -3.5 | -1.28 | 0.67 | -4.24 | -0.3 | -0.21 | -0.32 | -0.23 |
| Tax % | 33.33% | 100% | 0% | 100% | 0% | 7.43% | 0% | -7.46% | 0% | -10% | -33.33% | -12.5% | — |
| Net Profit | 0.02 | 0.01 | 0.01 | 0 | 0.03 | -3.76 | -1.28 | 0.72 | -4.23 | -0.27 | -0.13 | -0.28 | -0.18 |
| EPS in Rs | 0.03 | 0.02 | 0.02 | 0 | 0.05 | -6.43 | -2.19 | 1.23 | -7.23 | -0.46 | -0.22 | -0.48 | -0.3 |
| Div. Payout % | 0% | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 | 5.85 |
| Reserves | 1.21 | 1.21 | 1.19 | 1.18 | 1.18 | -2.64 | -3.92 | -3.2 | -7.42 | -7.22 | -7.34 | -7.62 |
| Borrowings | 9.25 | 9.01 | 9.94 | 11.32 | 5.35 | 2.85 | 2.5 | 1.32 | 1.33 | 1.36 | 1.49 | 1.8 |
| Other Liabilities | 2.32 | 2.34 | 3.97 | 5.01 | 9.46 | 1.52 | 1.2 | 0.91 | 0.31 | 0.06 | 0.08 | 0.04 |
| Total Liabilities | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.07 |
| Fixed Assets | 10.08 | 10.27 | 12.68 | 12.45 | 11.99 | 4.78 | 3.64 | 4.43 | 0 | 0 | 0 | 0 |
| CWIP | 0.2 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8.35 | 7.94 | 8.27 | 10.91 | 9.85 | 2.8 | 1.99 | 0.45 | 0.07 | 0.05 | 0.08 | 0.07 |
| Total Assets | 18.63 | 18.41 | 20.95 | 23.36 | 21.84 | 7.58 | 5.63 | 4.88 | 0.07 | 0.05 | 0.08 | 0.07 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0.39 | 0.83 | 2.46 | 0.89 | -0.95 | -11.34 | -0.29 | 0.21 | 0.01 | -0.17 | -0.23 | -0.16 |
| Investing | -2.44 | -0.21 | -3.18 | -0.37 | -0.28 | 11.24 | 0.12 | 0 | 0 | 0 | 0 | 0 |
| Financing | 2.18 | -0.78 | 0.63 | 1.04 | -0.29 | -0.02 | -0.03 | -0.01 | 0 | 0.15 | 0.25 | 0.16 |
| Net Cash Flow | 0.12 | -0.15 | -0.09 | 1.56 | -1.51 | -0.12 | -0.21 | 0.2 | 0.01 | -0.02 | 0.02 | 0 |
| Free Cash Flow | -2.06 | 0.62 | -0.73 | 0.36 | -1.23 | -0.1 | -0.17 | 0.21 | 0.01 | -0.17 | -0.23 | -0.16 |
| CFO/OP | 41 | 189 | 203 | 102 | -164 | 342 | 126 | -70 | -1 | 94 | 110 | 80 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57.74 | 53.87 | 56.3 | 103 | 136 | 79.2 | 91.11 | 34.53 | — | — | — | — |
| Inventory Days | 77.67 | 46.15 | 55.54 | 181 | 833 | 81.53 | 46.98 | 198 | 0 | — | — | — |
| Days Payable | 43.12 | 41.39 | 49.24 | 63.34 | 437 | 41.89 | 28.91 | 342 | — | — | — | — |
| Cash Conversion Cycle | 92.3 | 58.62 | 62.6 | 221 | 532 | 119 | 109 | -110 | — | — | — | — |
| Working Capital Days | 24.71 | -6.46 | -29.53 | -140 | -318 | -72 | -66.89 | -765 | — | — | — | — |
| ROCE % | 3.39% | 2.84% | 2% | 1.98% | 0.59% | -40.35% | -23.83% | -10.95% | 5.9% | — | — | -1266.67% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Adline Chem Lab insights
61 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Adline Chem Lab confirms it is not a Large Corporate; outstanding borrowing was Rs. 1.73 crore on March 31, 2026. 30 Apr - Adline Chem Lab confirms it is not a Large Corporate; outstanding borrowing was Rs. 1.73 crore on March 31, 2026.
2
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Company confirms it is not a Large Corporate; annual disclosure not required for FY2026. 30 Apr - Company confirms it is not a Large Corporate; annual disclosure not required for FY2026.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Adline Chem Lab confirms it is not a Large Corporate; outstanding borrowing was Rs. 1.73 crore on March 31, 2026. 30 Apr - Adline Chem Lab confirms it is not a Large Corporate; outstanding borrowing was Rs. 1.73 crore on March 31, 2026.
4
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Company confirms it is not a Large Corporate; annual disclosure not required for FY2026. 30 Apr - Company confirms it is not a Large Corporate; annual disclosure not required for FY2026.
5
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 Apr - Adline Chem Lab says annual secretarial compliance report not applicable for FY2026 under SEBI exemption. 29 Apr - Adline Chem Lab says annual secretarial compliance report not applicable for FY2026 under SEBI exemption.
Frequently Asked Questions about Adline Chem Lab
What does Adline Chem Lab Ltd do?
Incorporated in 1988, Adline Chem Lab Ltd trades in pharmaceutical formulations, Nutraceutical, and Dietary products.[1]
Where is Adline Chem Lab Ltd (524604) listed?
Adline Chem Lab Ltd trades as KAMRONLABORATORIESLTD on the NSE and under code 524604 on the BSE.
Which sector does Adline Chem Lab Ltd belong to?
Adline Chem Lab Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Adline Chem Lab Ltd?
Adline Chem Lab Ltd has a market capitalisation of ₹6.7 Cr, which places it in the Small Cap band.
What is the PE ratio of Adline Chem Lab Ltd?
Adline Chem Lab Ltd trades at a PE ratio of -36.00, against a book value of ₹-3.03 per share.
What is the 52-week high and low of Adline Chem Lab Ltd?
Over the last 52 weeks Adline Chem Lab Ltd has traded between ₹7.6 and ₹17.06.
What is the Return on Equity (ROE) of Adline Chem Lab Ltd?
Adline Chem Lab Ltd reported a return on equity of 15.84%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1988, Adline Chem Lab Ltd trades in pharmaceutical formulations, Nutraceutical, and Dietary products.[1]
Website kamronlabs.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524604.md for Adline Chem Lab Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.